In brief: NPG #14 requires hospitals to reduce the likelihood of patient harm associated with anticoagulant therapy, because these drugs carry high risk through complex dosing, insufficient monitoring and inconsistent patient adherence (Joint Commission, 2025). Most anticoagulant-associated adverse drug events in inpatients result from medication errors and are therefore potentially preventable (Piazza et al., 2011).
Prof. Dr. Mehmet Nurullah Kurutkan, Düzce University, Faculty of Business, Department of Health Management
Abstract. Part 6 examines anticoagulant safety, added to the Joint Commission requirements in 2017. Based on 298 hospital records from a 4,936-record Web of Science corpus, the chapter explains why anticoagulants are among the leading causes of adverse drug events, how the arrival of direct oral anticoagulants (DOACs) changed rather than removed the risk, and how pharmacist-managed anticoagulation services and the newer concept of anticoagulation stewardship try to control it. The evidence shows persistent, preventable harm with only marginal improvement over time, and strong support for structured, pharmacist-involved management.
Series: Effectively Managing Medications (Joint Commission NPG #14)
- Series guide: Effectively Managing Medications (NPG #14)
- Part 1. Pharmacist Order Review When the Pharmacy Is Closed
- Part 2. Automated Dispensing Cabinets and Overrides
- Part 3. Medication Selection, Procurement and Shortages
- Part 4. Perioperative and Procedural Medication Labeling
- Part 5. Medication Reconciliation
- Part 6. Anticoagulant Safety (you are here)
- Part 7. Antimicrobial Stewardship in Hospitals
Learning objectives
After completing this chapter, the reader will be able to:
- Explain why anticoagulants are high-alert medications and why NPG #14 addresses them separately.
- Describe common anticoagulant error types for warfarin, heparins and DOACs.
- Define anticoagulation management services and anticoagulation stewardship.
- Summarise evidence on pharmacist-managed anticoagulation and DOAC stewardship programmes.
- Identify limitations of voluntary reports and administrative codes for measuring anticoagulant harm.
- Draft components of a hospital anticoagulation safety programme.
Key concepts: anticoagulant, direct oral anticoagulant (DOAC), warfarin, unfractionated and low-molecular-weight heparin, time in therapeutic range (TTR), anticoagulation management service, anticoagulation stewardship, adverse drug event (ADE)
Contents
- 1. Introduction
- 2. History and development
- 3. Definitions and conceptual schema
- 4. Distinguishing neighbouring concepts
- 5. Types and classifications
- 6. Theoretical frameworks and models
- 7. Themes and bibliometric profile
- 8. The situation in Türkiye
- 9. Debates and contradictions in the literature
- 10. Measurement problems
- 11. Research gaps and agenda
- 12. Relevance today and practical implications
- Summary box, discussion questions, further reading, glossary and references
Method box: how this chapter was produced
| Component | Application |
|---|---|
| Source document | Joint Commission (2025), National Performance Goal #14 “Effectively Managing Medications” (formerly part of the National Patient Safety Goals). (Joint Commission, 2025) |
| Database and indexes | Web of Science Core Collection (SCI-EXPANDED, SSCI, ESCI) |
| Search strategy (series) | Seven component blocks derived from the NPG #14 requirements, a core medication safety block and a hospital context block; combined set #24 = ((#1 AND component blocks 1-4) OR medication reconciliation OR anticoagulant block) AND hospital block, OR the title-based stewardship block; filtered to articles and reviews, English, 2000-2026. |
| Component query (this chapter) | (core medication safety block AND TI=(anticoagula* OR warfarin OR heparin OR enoxaparin OR "low-molecular-weight heparin" OR "direct oral anticoagulant*" OR DOAC* OR NOAC* OR apixaban OR rivaroxaban OR dabigatran OR edoxaban)) OR TS=("anticoagulation stewardship" OR "anticoagulant stewardship" OR "anticoagulation management service*" OR "anticoagulation management program*" OR "pharmacist-managed anticoagulation" OR "pharmacist-led anticoagulation" OR "anticoagulation safety") |
| Core block | TS=("medication safety" OR "medication error*" OR "medication mistake*" OR "drug error*" OR "prescribing error*" OR "prescription error*" OR "dispensing error*" OR "administration error*" OR "transcription error*" OR "adverse drug event*" OR "preventable adverse drug*" OR "medication-related harm" OR "medication incident*" OR "medication management" OR "medication use process" OR "safe medication" OR "high-alert medication*" OR "wrong drug" OR "wrong dose" OR "wrong route") |
| Search date and span | 16 November 2026; publication years 2000-2026 (2027 early-access records retained) |
| Inclusion and exclusion | Included: hospital-context records matching this component. Excluded: retracted publications and records whose only labeling match was “open-label”. |
| Screening counts | Series corpus 4,936; tagged for this component 298; excluded 0; eligible 298; core evidence set (component term in title or author keywords) 154; “patient safety” framed 59. |
| Evidence extraction | Definitions, milestones, models, measures, debates and gaps were extracted from the abstracts of the most cited and most recent records in the core set. |
| Limitations | Single database; English only; component tagging is rule based and reproduces the WoS query on title, abstract and keywords (agreement within 5 records per component); evidence read at abstract level; full texts were not read. |
1. Introduction
Anticoagulants protect against strokes and clots but cause bleeding when dosed too high and clots when dosed too low. A five-year analysis of hospitalised patients found that most anticoagulant-associated adverse drug events resulted from medication errors, that affected patients had elevated 30-day mortality and that costs were high (Piazza et al., 2011). A follow-up across two time periods found that such events remained common despite new technologies, with prescribing errors as the most frequent root cause (Fanikos et al., 2023).
For these reasons the Joint Commission updated its standards in 2017 to address anticoagulant risk, and NPG #14 now requires hospitals to reduce the likelihood of harm associated with anticoagulant therapy (Joint Commission, 2025).
2. History and development
Early research focused on warfarin and heparin. In 2000, daily consultation by a pharmacist-managed anticoagulation service shortened hospital stay and reduced excessive anticoagulation (Dager et al., 2000). In 2004, medication errors with anticoagulants in hospital were shown to be frequent (Fanikos et al., 2004), and voluntary reports were used to describe warfarin errors in 2008 (Zhan et al., 2008). Around 2010-2012, studies compared models of anticoagulation management services and their costs (Hall et al., 2011; Rudd & Dier, 2010) and showed that pharmacist-managed clinics also work in resource-limited settings (Manji et al., 2011; Saokaew et al., 2012).
The arrival of DOACs shifted attention to inappropriate prescribing (Larock et al., 2014) and DOAC-specific errors (Al Rowily et al., 2022; Haque et al., 2021). From 2019 the term stewardship appeared: hospital-wide DOAC stewardship led by clinical pharmacists (Perlman et al., 2019), anticoagulation stewardship teams (Koolian et al., 2022) and case-based guidance (May et al., 2025). The Joint Commission added anticoagulant requirements in 2017 (Joint Commission, 2025).
3. Definitions and conceptual schema
Definitions combine the harm (adverse drug events) and the organisational response (management services and stewardship).
| Source | Year | Discipline | Definition (paraphrased) | Emphasised dimension |
|---|---|---|---|---|
| Fanikos et al. (2023) | 2023 | Internal medicine | Anticoagulant ADEs comprise medication errors and adverse drug reactions in patients receiving anticoagulants. | Harm from errors and reactions |
| Manzoor et al. (2017) | 2017 | Pharmacotherapy | Pharmacist-managed anticoagulation services monitor and adjust therapy to achieve anticoagulation control, compared with routine care. | Quality of control (TTR) |
| Su et al. (2023) | 2023 | Clinical pharmacology | Medicines stewardship is coordinated strategies to optimise medicine use within a therapeutic area, a continual quality improvement process. | Programme and governance |
| Koolian et al. (2022) | 2022 | Thrombosis | An anticoagulation stewardship team reviews inpatient prescriptions and recommends dose adjustments and interaction changes. | Prescription optimisation |
| Joint Commission (2025) | 2025 | Accreditation | Hospitals reduce the likelihood of patient harm associated with anticoagulant therapy. | Harm reduction requirement |
The shared core is organised oversight of a high-risk drug class. Definitions diverge on setting (inpatient or outpatient), on the measure of success (time in therapeutic range, errors, bleeding) and on whether the response is a clinical service for individual patients or a stewardship programme for the whole organisation.
4. Distinguishing neighbouring concepts
Anticoagulant safety overlaps with high-alert medication management, anticoagulation management services (clinics), anticoagulation stewardship and pharmacovigilance. Management services focus on individual patients’ control (Manzoor et al., 2017); stewardship applies programme logic to the whole organisation, borrowing from antimicrobial stewardship (Su et al., 2023); pharmacovigilance studies adverse reactions at population level, for example bleeding visits to emergency departments (Geller et al., 2023).
5. Types and classifications
Error and harm types differ by drug class.
| Drug class | Typical problems | Corpus source |
|---|---|---|
| Warfarin | INR outside range, interactions, poor control after discharge | (Stafford et al., 2011; Zhan et al., 2008) |
| Unfractionated and low-molecular-weight heparin | Dosing not adjusted to weight, supratherapeutic aPTT, bolus and rate errors | (Booth et al., 2024; Cossette et al., 2010) |
| DOACs | Inappropriate dose for indication or renal function, interactions | (Al Rowily et al., 2022; Haque et al., 2021; Larock et al., 2014) |
| All classes | Prescribing errors as the leading root cause | (Fanikos et al., 2023) |
Management models range from usual medical care to nurse-managed and pharmacist-managed services and collaborative clinics (Rudd & Dier, 2010).
6. Theoretical frameworks and models
Studies draw on the Reason accident causation model, which shows that latent system failures contributed to most DOAC-related incidents (Haque et al., 2021). Programme models borrow from stewardship: multidisciplinary leadership, stakeholder engagement, behaviour change, implementation science and ongoing monitoring (Su et al., 2023).
Service models are evaluated against quality of anticoagulation control, mainly time in therapeutic range, and against bleeding and thromboembolic outcomes (Manzoor et al., 2017).
7. Themes and bibliometric profile
The eligible subcorpus holds 298 records (26 of them reviews) with 3,793 citations in the WoS Core Collection. 36 records appeared in 2000-2010 and 216 in 2016-2026, so most of the evidence is recent (Figure 5). The leading journals are Journal of Thrombosis and Thrombolysis (19), Annals of Pharmacotherapy (15), International Journal of Clinical Pharmacy (15), American Journal of Health-system Pharmacy (14). By author address the most active countries are United States (151), Australia (20), China (18), Canada (18), England (17). The most frequent author keywords are: warfarin, anticoagulation, anticoagulants, medication safety, medication errors, direct oral anticoagulants, adverse drug events, patient safety, atrial fibrillation, venous thromboembolism. 59 records (20%) explicitly frame their topic with the term “patient safety”.
Themes are (1) frequency and cost of anticoagulant ADEs (Fanikos et al., 2023; Piazza et al., 2011); (2) pharmacist-managed services (Dager et al., 2000; Hall et al., 2011; Manzoor et al., 2017); (3) DOAC prescribing and errors (Al Rowily et al., 2022; Larock et al., 2014); (4) protocols and stewardship (May et al., 2025; Perlman et al., 2019; Willeford et al., 2021); (5) surveillance of bleeding (Geller et al., 2023; Shehab et al., 2019).
8. The situation in Türkiye
No record in the anticoagulant subcorpus has a Turkish address. The corpus therefore provides no evidence on anticoagulant safety programmes in Turkish hospitals.
9. Debates and contradictions in the literature
Axis 1: have DOACs solved the safety problem? DOACs have a favourable safety profile, yet DOAC errors are common (Al Rowily et al., 2022), inappropriate prescribing is frequent (Larock et al., 2014) and emergency visits for anticoagulant bleeding remained high despite increased DOAC use (Geller et al., 2023).
Axis 2: has hospital anticoagulant safety improved? Comparing two periods, ADE types, root causes and harm were similar, suggesting only marginal improvement (Fanikos et al., 2023). Single-site protocols report large reductions, for example a 44% fall in DOAC-related errors after a pharmacist-to-dose protocol (Willeford et al., 2021).
Axis 3: which management model is best? Pharmacist-managed services achieved better control and lower costs than usual care (Hall et al., 2011; Manzoor et al., 2017), while a comparison of models suggested that a collaborative clinic with pharmacists, nurses and physicians may be optimal (Rudd & Dier, 2010).
10. Measurement problems
Voluntary reports provide actionable information but suffer from missing detail, under-reporting and biases (Zhan et al., 2008). Administrative codes miss most anticoagulant-related bleeding: adverse-effect codes would have missed over 90% of cases (Shehab et al., 2019).
Time in therapeutic range is a good measure for warfarin but does not apply to DOACs, for which appropriateness of dose relative to renal function and indication is used instead (Larock et al., 2014). Stewardship studies mostly report process changes and call for evaluation of clinical outcomes (Koolian et al., 2022).
11. Research gaps and agenda
The following questions are framed so that they can be answered by empirical studies; each notes the evidence gap it derives from.
- Do anticoagulation stewardship programmes reduce bleeding and thrombosis, not only prescription changes? (Outcome evaluation is called for.)
- Which surveillance method best detects anticoagulant harm in hospitals? (Reports and codes both miss events.)
- Why has hospital anticoagulant safety improved only marginally despite new technologies? (Similar ADE profiles across periods.)
- Which DOAC errors are most harmful, and which interventions prevent them? (Causality assessments often missing.)
- What is the burden of anticoagulant ADEs in Turkish hospitals? (No Turkish record.)
- How should stewardship extend across transitions to primary care? (Programmes are mostly hospital based.)
12. Relevance today and practical implications
A hospital anticoagulant programme for NPG #14 can include: approved protocols for heparin and DOAC dosing with renal adjustment; pharmacist review or pharmacist-to-dose protocols (Willeford et al., 2021); baseline and follow-up laboratory monitoring; interaction alerts; patient education at discharge (Stafford et al., 2011); and a stewardship team that tracks errors, bleeding and reversal-agent use (Koolian et al., 2022; May et al., 2025).
Summary box
- Anticoagulants are a leading cause of preventable adverse drug events in hospitals.
- NPG #14 requires hospitals to reduce harm associated with anticoagulant therapy.
- DOACs changed the error profile but did not remove risk.
- Pharmacist-managed services and protocols improve control and reduce errors.
- Anticoagulation stewardship is an emerging organisation-wide model.
- Voluntary reports and administrative codes under-detect harm.
Discussion questions
- Why are most anticoagulant ADEs in hospital considered preventable?
- What new error types did DOACs introduce?
- Compare an anticoagulation clinic with an anticoagulation stewardship programme.
- Why are administrative codes poor at detecting anticoagulant bleeding?
- Application: write the core elements of an anticoagulation stewardship policy for a 400-bed hospital.
- Application: choose three indicators for monthly anticoagulant safety monitoring.
Further reading
- Piazza et al. (2011): foundational study of anticoagulant ADEs and costs.
- Fanikos et al. (2023): shows how little has changed over time.
- Al Rowily et al. (2022): systematic review of DOAC errors.
- Manzoor et al. (2017): evidence for pharmacist-managed services.
- May et al. (2025): practical cases in anticoagulation stewardship.
Glossary
| Term | Turkish | Short definition |
|---|---|---|
| Anticoagulant | Antikoagülan | Drug that reduces blood clotting. |
| DOAC | Doğrudan etkili oral antikoagülan | Oral anticoagulant acting directly on thrombin or factor Xa. |
| Time in therapeutic range | Terapötik aralıkta kalma süresi | Share of time INR stays in target range. |
| Anticoagulation stewardship | Antikoagülan yönetim programı | Organisation-wide programme to optimise anticoagulant use. |
| Adverse drug event | İlaç advers olayı | Injury resulting from a medication. |
| High-alert medication | Yüksek riskli ilaç | Drug with heightened risk of harm when used in error. |
| aPTT | aPTZ | Laboratory test used to monitor unfractionated heparin. |
References
Al Rowily, A., Jalal, Z., Price, M. J., Abutaleb, M. H., Almodiaemgh, H., Al Ammari, M., & Paudyal, V. (2022). Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 78(4), 623-645. https://doi.org/10.1007/s00228-021-03212-y
Booth, D. Y., Cherian, S. M., Lark, J., Stratton, M., & Babu, R. N. (2024). IMPLEMENTATION OF A HEPARIN INFUSION CALCULATOR IN THE ELECTRONIC HEALTH RECORD SYSTEM AS A RISK-MITIGATION STRATEGY IN A COMMUNITY TEACHING HOSPITAL EMERGENCY DEPARTMENT. Journal of Emergency Nursing, 50(1), 36-43. https://doi.org/10.1016/j.jen.2023.10.002
Cossette, B., Pelletier, M., Carrier, N., Turgeon, M., Leclair, C., Charron, P., Echenberg, D., Fayad, T., & Farand, P. (2010). Evaluation of Bleeding Risk in Patients Exposed to Therapeutic Unfractionated or Low-Molecular-Weight Heparin: A Cohort Study in the Context of a Quality Improvement Initiative. Annals of Pharmacotherapy, 44(6), 994-1002. https://doi.org/10.1345/aph.1M615
Dager, W. E., Branch, J. M., King, J. H., White, R. H., Quan, R. S., Musallam, N. A., & Albertson, T. E. (2000). Optimization of inpatient warfarin therapy: Impact of daily consultation by a pharmacist-managed anticoagulation service. Annals of Pharmacotherapy, 34(5), 567-572. https://doi.org/10.1345/aph.18192
Fanikos, J., Stapinski, C., Koo, S., Kucher, A., Tsilimingras, K., & Goldhaber, S. Z. (2004). Medication errors associated with anticoagulant therapy in the hospital. American Journal of Cardiology, 94(4), 532-535. https://doi.org/10.1016/j.amjcard.2004.04.075
Fanikos, J., Tawfik, Y., Almheiri, D., Sylvester, K., Buckley, L. F., Dew, C., Dell’Orfano, H., Armero, A., Bejjani, A., Bikdeli, B., Campia, U., Davies, J., Fiumara, K., Hogan, H., Khairani, C. D., Krishnathasan, D., Lou, J. Y., Makawi, A., Morrison, R. H., . . ., & Piazza, G. (2023). Anticoagulation-Associated Adverse Drug Events in Hospitalized Patients Across Two Time Periods. American Journal of Medicine, 136(9), 927. https://doi.org/10.1016/j.amjmed.2023.05.013
Geller, A. I., Shehab, N., Lovegrove, M. C., Weidle, N. J., & Budnitz, D. S. (2023). Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016-2020. Thrombosis Research, 225, 110-115. https://doi.org/10.1016/j.thromres.2023.03.010
Hall, D., Buchanan, J., Helms, B., Eberts, M., Mark, S., Manolis, C., Peele, P., & Docimo, A. (2011). Health Care Expenditures and Therapeutic Outcomes of a Pharmacist-Managed Anticoagulation Service versus Usual Medical Care. Pharmacotherapy, 31(7), 686-694. https://doi.org/10.1592/phco.31.7.686
Haque, H., Alrowily, A., Jalal, Z., Tailor, B., Efue, V., Sarwar, A., & Paudyal, V. (2021). Direct oral anticoagulant-related medication incidents and pharmacists’ interventions in hospital in-patients: evaluation using reason’s accident causation theory. International Journal of Clinical Pharmacy, 43(6), 1693-1704. https://doi.org/10.1007/s11096-021-01302-6
Joint Commission. (2025). Effectively managing medications (National Performance Goal #14) [Fact sheet]. https://digitalassets.jointcommission.org/api/public/content/d0c3745c2d7e494ca5199bd3af2a13bc
Koolian, M., Wiseman, D., Mantzanis, H., Kampouris, N., Kerzner, R. S., & Kahn, S. R. (2022). Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription. Research and Practice in Thrombosis and Haemostasis, 6(6), e12758. https://doi.org/10.1002/rth2.12758
Larock, A. S., Mullier, F., Sennesael, A. L., Douxfils, J., Devalet, B., Chatelain, C., Dogné, J. M., & Spinewine, A. (2014). Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation: A Prospective Study. Annals of Pharmacotherapy, 48(10), 1258-1268. https://doi.org/10.1177/1060028014540868
Manji, I., Pastakia, S. D., Do, A. N., Ouma, M. N., Schellhase, E., Karwa, R., Miller, M. L., Saina, C., & Akwanalo, C. (2011). Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. Journal of Thrombosis and Haemostasis, 9(11), 2215-2220. https://doi.org/10.1111/j.1538-7836.2011.04503.x
Manzoor, B. S., Cheng, W. H., Lee, J. C., Uppuluri, E. M., & Nutescu, E. A. (2017). Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review. Annals of Pharmacotherapy, 51(12), 1122-1137. https://doi.org/10.1177/1060028017721241
May, J. E., Allen, A. L., Bannow, B. T. S., O’Connor, C., Sylvester, K. W., & Kaatz, S. (2025). Safe and effective anticoagulation use: case studies in anticoagulation stewardship. Journal of Thrombosis and Haemostasis, 23(3), 779-789. https://doi.org/10.1016/j.jtha.2024.11.024
Perlman, A., Horwitz, E., Hirsh-Raccah, B., Aldouby-Bier, G., Negev, T. F., Hochberg-Klein, S., Kalish, Y., & Muszkat, M. (2019). Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Israel Journal of Health Policy Research, 8, 19. https://doi.org/10.1186/s13584-019-0285-9
Piazza, G., Nguyen, T. N., Cios, D., Labreche, M., Hohlfelder, B., Fanikos, J., Fiumara, K., & Goldhaber, S. Z. (2011). Anticoagulation-associated Adverse Drug Events. American Journal of Medicine, 124(12), 1136-1142. https://doi.org/10.1016/j.amjmed.2011.06.009
Rudd, K. M., & Dier, J. G. (2010). Comparison of Two Different Models of Anticoagulation Management Services with Usual Medical Care. Pharmacotherapy, 30(4), 330-338. https://doi.org/10.1592/phco.30.4.330
Saokaew, S., Sapoo, U., Nathisuwan, S., Chaiyakunapruk, N., & Permsuwan, U. (2012). Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. International Journal of Clinical Pharmacy, 34(1), 105-112. https://doi.org/10.1007/s11096-011-9597-8
Shehab, N., Ziemba, R., Campbell, K. N., Geller, A. I., Moro, R. N., Gage, B. F., Budnitz, D. S., & Yang, T. H. (2019). Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries. Pharmacoepidemiology and Drug Safety, 28(7), 951-964. https://doi.org/10.1002/pds.4783
Stafford, L., Peterson, G. M., Bereznicki, L. R. E., Jackson, S. L., Van Tienen, E. C., Angley, M. T., Bajorek, B. V., McLachlan, A. J., Mullan, J. R., Misan, G. M. H., & Gaetani, L. (2011). Clinical Outcomes of a Collaborative, Home-Based Postdischarge Warfarin Management Service. Annals of Pharmacotherapy, 45(3), 325-334. https://doi.org/10.1345/aph.1P617
Su, E., Liew, D. F. L., Donnelly, J., & Elliott, R. A. (2023). Medicines stewardship. Australian Prescriber, 46(2), 24-28. https://doi.org/10.18773/austprescr.2023.010
Willeford, A., Leiman, V., & Noel, Z. R. (2021). Impact of a pharmacist-to-dose direct oral anticoagulant protocol on medication errors at an academic medical center. Journal of the American College of Clinical Pharmacy, 4(11), 1392-1400. https://doi.org/10.1002/jac5.1503
Zhan, C. L., Smith, S. R., Keyes, M. A., Hicks, R. W., Cousins, D. D., & Clancy, C. M. (2008). How Useful Are Voluntary Medication Error Reports? The Case of Warfarin-Related Medication Errors. Joint Commission Journal on Quality and Patient Safety, 34(1), 36-45. https://doi.org/10.1016/S1553-7250(08)34006-9
Source verification note
Author names, year, journal and DOI details of the 23 corpus-based citations were generated by code directly from the Web of Science records and checked one to one against the in-text citations; claims were checked at the level of record abstracts, and full texts were not read. The Joint Commission fact sheet was read in full on 16 November 2026. No source outside the corpus and the fact sheet is cited.
AI use statement
Anthropic’s Claude model was used to design and run the Web of Science search, tag and pre-screen records, extract evidence from abstracts, draft the English text and produce the figures. Final decisions, the scientific accuracy of the text and final responsibility rest with the author.
Data and supplementary material
The full list of the 154 core records and the 298 eligible records for this part (author, year, title, journal, DOI, component flags, “patient safety” layer flag and pre-screening suggestion), the screening log of the 4,936-record series corpus and the citation verification report are provided in the series companion workbook (NPG14_Series_Supplementary.xlsx), available from the author on request. The record list is deliberately kept out of the chapter text.
Series: Effectively Managing Medications (Joint Commission NPG #14)
- Series guide: Effectively Managing Medications (NPG #14)
- Part 1. Pharmacist Order Review When the Pharmacy Is Closed
- Part 2. Automated Dispensing Cabinets and Overrides
- Part 3. Medication Selection, Procurement and Shortages
- Part 4. Perioperative and Procedural Medication Labeling
- Part 5. Medication Reconciliation
- Part 6. Anticoagulant Safety (you are here)
- Part 7. Antimicrobial Stewardship in Hospitals
Cite this page (APA 7)
Kurutkan, M. N. (2026, November 16). Anticoagulant Safety: An Introduction (101). The Health Topics. https://healthtopic.org/topics/anticoagulant-safety-an-introduction-101/
